Oncology Pipeline
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.
Next-Generation RET Inhibitor
LOXO-260

Mulligan LM1
Target
Recently, resistance to targeted RET treatment has been described in the clinic with secondary solvent front mutations or other oncogenic pathway activations emerging.12-14
Molecule
Clinical Development
References
- Mulligan LM. Nat Rev Cancer. 2014;14:173-186.
- Lipson D, et al. Nat Med. 2012;18(3):382-384.
- Takeuchi K, et al. Nat Med. 2012;18(3):378-381.
- Bounacer A, et al. Oncogene. 1997;15(11):1263-1273.
- Prescott JD, Zeiger MA. Cancer. 2015;121(13):2137-2146.
- Ballerini P, et al. Leukemia. 2012;26(11):2384-2389.
- Bossi D, et al. Mol Oncol. 2014;8(2):221-231.
- Stransky N, et al. Nat Commun. 2014;5:4846.
- Hofstra RM, et al. Nature. 1994;367(6461):375-376.
- Agrawal N, et al. J Clin Endocrinol Metab. 2013;98(2):E364-E369.
- Taccaliti A, et al. Curr Genomics. 2011;12(8):618-625.
- Solomon BJ, et al. J Thorac Oncol. 2020;15(4):541-549.
- Subbiah V, et al. Ann Oncol. 2021b;32(2):261-268.
- Rosen EY, et al. Clin Cancer Res. 2021;27(1):34-42.
- AACR disclosure. Kolakowski et al. Pre-clinical characterization of potent and selective next-generation RET inhibitors. Presented at AACR Annual Meeting 2021; April 10, 2021.
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.